Fibromyalgia and Exclzyme
Fibromyalgia is derived from the Latin roots fibro (fibrous tissue), my (muscles), al (pain), and gia (condition of), a literal evaluation of the syndrome, but current research is finding this condition to be much more complex than originally theorized.
Symptoms of fibromyalgia include widespread pain with multiple tender points, fatigue, sleep disturbances and anxiety or depression; however many of these symptoms overlap with other conditions, such as chronic fatigue syndrome and Gulf War syndrome, making it more difficult to identify. The sequence of events that causes fibromyalgia remains unknown, but advances and discoveries may help to unravel the mysteries of this disease.
A popular theory for fibromyalgia causation is the development of chronic hypercoagulation, or excessive blood clotting. Normally, the body activates the release of thrombin, a protein responsible for the formation of fibrin, after a traumatic event or infection to help promote the formation of protective blood clots. According to some researchers, this mechanism is not “turned off” when the trauma or infection subsides, but rather a low level of thrombin continues to be produced. This chronic thrombin production creates higher fibrin levels in the blood that increases blood thickness and forms clots, both of which can create ischemic pain throughout the body.1 While verifying studies are available that supports this theory, contradicting evidence that is just as strong also exists and newer concepts have gained greater support.2,3
The current theory for the pathophysiology of fibromyalgia is that it is a disorder of central pain processing, a concept called central sensitization. This implies that the syndrome is a widespread problem of sensory volume control, meaning that the patient’s pain threshold has been altered so that pain stimuli are perceived as being much stronger than they really are.4 Neurobiologic changes have been noted that affect the perception of pain, such as a decrease in serotonin levels, ATP and growth hormones and the increase in the neurotransmitter Substance P, which increases sensitivity to and awareness of pain. These neurochemical changes help to explain psychological symptoms of fibromyalgia as well.5
The complexity of fibromyalgia pain has limited the available treatment options for patients. There is no cure for fibromyalgia and no single treatment capable of addressing all symptoms. Therapies and treatment plans have been established to help reduce pain, alleviate symptoms and improve quality of life. The difficulty with most prescription drugs, however, is that they carry side effects that can be as debilitating as the condition itself.
Exclzyme is a proprietary blend of powerful systemic enzymes and herbs formulated to support healthy circulation, fibrin metabolism and support the body’s normal inflammatory and healing processes. Systemic enzymes have successfully demonstrated the ability to reduce signs of pain throughout the body. Serrapeptase, an enzyme extracted from silk worms, has been evaluated in numerous studies for its effectiveness in pain reduction and shown favorable results. 6,7 What’s more, systemic enzymes have not been shown to produce adverse effects when taken properly, even in higher dosages.8
Incorporating Exclzyme into a pain relief regimen can be a key part to addressing fibromyalgia syndrome.
Learn more about Exclzyme
1. Berg DE, Berg LH, Harrison HH. Low Level Activation of Coagulation with Coagulopathies in the Etiology of CFS/FM and Chronic Illnesses. An explanatory Model Revisited. HEMEX Laboratories, Phoenix, Az, Univ AZ College of Medicine. VIIth International Conference, AACFS Meeting, Madison, WI, Oct, 2004.
2. Berg D, Berg LH, Couvaras J, Harrison H. Chronic fatigue syndrome &/or fibromyalgia as a variation of antiphospholipid antibody syndrome (APS): An explanatory model and approach to laboratory diagnosis. Blood Coagulation and Fibrinolysis 1999: 10 435-438.
3. Kennedy, G, Norris G, Spence V, McLaren M, Belch JJF. Is chronic fatigue syndrome associated with platelet activation? Blood Coagulation and Fibrinolysis 2006; 17:89–92
4. Clauw DJ. Fibromyalgia: more than just a musculoskeletal disease. Am Fam Physician. Sep 1 1995; 52(3):843-51, 853-4.
5. Bradley LA. Pathophysiology of Fibromyalgia. Am J Med. 2009 December; 122(12 Suppl): S22.
6. Klein G, Kullich W. Reducing pain by oral enzyme therapy in rheumatic diseases. Wien Med Wochenschr. 1999; 149(21-22):577-80.
7. Mazzone A, Catalani M, Costanzo M, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. 1990; 18(5):379-88.
8. Viswanatha Swamy AHM, Patil PA. Effect of Some Clinically Used Proteolytic Enzymes on Inflammation in Rats. Indian Journal of Pharmaceutical Sciences. 2008; 70(1):114-117.